Monjuvi

Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody indicated, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). Tafasitamab binds to the CD19 antigen on pre-B and mature B lymphocytes, inducing B-cell lysis via apoptosis and immune effector mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis. <a id="